Ngomhlaka-10 kuNhlolanja 2025, i-CARsgen Therapeutics imemezela ukuthi umuntu wokuqala ophathwe ngokwelashwa kwe-BCMA CAR-T okune-allogeneic okwakhiwe epulatifomu ye-THANK-u Plus™, uthole impendulo ephelele eqinile (sCR) kanye nokungalungi okuncane kwesifo (MRD) ekuhlolweni kosuku lwama-28. Ipulatifomu ye-THANK-u Plus™ yakhelwe ngaphakathi, ubuchwepheshe obusha be-allogeneic CAR-T obuklanyelwe ukunqoba izinselele zokufinyeleleka ekwelashweni kwe-CAR-T.
Isiguli, esitholakale sine-myeloma ephindaphindayo/engasasebenzi kahle, uhlobo lwe-IgA-λ (R-ISS Stage II), sasike sathola imigqa emithathu yokwelashwa okuhlanganisiwe kanye nokufakelwa kweseli le-stem le-hematopoietic autologous. Ngemva kokuqhubeka kwesifo ngemuva kokwelashwa kwakamuva, isiguli sabhaliswa esivivinyweni somtholampilo. Ngemva kokufakwa kwamaseli e-CAR T ezingeni eliphansi kakhulu ngokwenqubo yezokwelapha, isiguli sathola i-Grade 1 cytokine release syndrome (CRS), eyaphathwa ngempumelelo ngemithi yokulwa ne-pyretics kanye ne-tocilizumab, futhi isiguli asizange sibonise i-immune effect cell-associated neurotoxicity syndrome (ICANS) noma ezinye izehlakalo ezingezinhle ezihlobene ne-CAR-T immune, okubonisa iphrofayili yokuphepha enhle iyonke.
Lolu hlobo lokwelashwa lwe-CAR-T lwenzelwe ukwelapha i-relapse/refractory multiple myeloma (R/R MM) kanye ne-relapse/refractory plasma cell leukemia (R/R PCL). Kulindeleke ukuthi kube nokubuyekezwa kwedatha okwengeziwe engxenyeni yesibili yalo nyaka.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
Email：myimmnet@163.com
Izinkomba
2.https://www.prnasia.com/
Isikhathi sokuthunyelwe: Feb-11-2025